BioCentury
ARTICLE | Clinical News

Ascletis' HCV regimen moving along in Taiwan, China

June 22, 2016 12:15 AM UTC

Ascletis Pharmaceuticals Co. Ltd. (Shaoxing, China) said it observed a 100% virologic response rate after 12 weeks of treatment in the Taiwanese Phase II EVEREST study of danoprevir ( ASC08) plus ravidasvir ( ASC16) to treat HCV. The company presented the interim data at the Asian Pacific Association for the Study of the Liver Single Topic Conference in HCV.

Ascletis also said it began a clinical trial in China of the same combo to treat HCV. The company did not respond to inquiries regarding the trial. In April, China FDA selected ravidasvir for expedited review via a new approval pathway (see BioCentury Extra, April 25). ...